The Baltimore Sun recently published a six-part series that examines the lives of four women living with terminal breast cancer who enrolled in an experimental vaccine trial run by Leisha Emens, an oncologist at Johns Hopkins Hospital. Headlines appear below.~ "

Women with a particularly aggressive form of early stage (primary) breast cancer may miss out on optimal treatment which may include chemotherapy and trastuzumab (Herceptin) as a result of untimely or missing HER2-status test results, according to doctors responding to the results from a North of England Cancer Network audit of HER2-testing today.

Although genetic testing can provide some women with information about their risk for breast cancer, women who receive inconclusive results from genetic testing might be left with persistent anxiety, according to a study published recently in the journal Genetics in Medicine,

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Australia Pty Ltd, today announced that approval has been received from the Therapeutic Goods Administration (TGA) in Australia to market ABRAXANE® (nanoparticle albumin-bound paclitaxel) 100 mg powder for injection (suspension) for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.

The University of Newcastle has received a record $14.8 million from the National Health and Medical Research Council (NHMRC). Funding for four research projects into asthma, breast cancer, stroke and mental illness accounts for almost half of the total amount awarded to the University. Professor Barney Glover, Deputy Vice-Chancellor (Research), said the funding would support 18 research projects as well as infrastructure and equipment.

Benefact has launched the "Will for a Cure" campaign for Breast Cancer Awareness month to raise money for breast cancer research. This is the first fundraising event of its kind. The campaign asks everyone who wants to help breast cancer research and who has not completed their will to go to http://www.willforacure.

As millions of Americans participate in educational initiatives as part of National Breast Cancer Awareness Month, they should keep in mind an important yet under-recognized consequence of breast cancer therapy: oral mucositis, one of the most common and debilitating side effects of cancer treatment. Oral mucositis (OM) is a painful inflammation/ulceration of the mucous membranes in the mouth.

Part of black women's "increased vulnerability to breast cancer is a result of differential access to health care and health services," Julianne Malveaux, president of Bennett College for Women, writes in a Seattle Medium opinion piece. She notes that October is

STUTTGART, GERMANY (UroToday.com) - The impact of microscopic versus macroscopic vascular invasion on metastasis-free survival was analyzed in 2,394 re-evaluated kidney cancer specimens from Graz (Austria). Vascular invasion was present in 22.8% of all specimens (16.6% macroscopic and 6.2% microscopic). At an average follow-up of 85 months, 25.4% of all patients had developed metastases.

As millions of Americans participate in educational initiatives as part of National Breast Cancer Awareness Month, they should keep in mind an important yet under-recognized consequence of breast cancer therapy: oral mucositis, one of the most common and debilitating side effects of cancer treatment. Oral mucositis (OM) is a painful inflammation/ulceration of the mucous membranes in the mouth.

Deerfield Urethane, Inc. (Deerfield), a wholly owned subsidiary of Bayer MaterialScience LLC (BMS) and one of the leading suppliers of custom, made-to-order thermoplastic polyurethane (TPU) and specialty elastomer film and sheet, is proud to announce its collaboration with BHS International (BHS), a breast health company co-founded by Olivia Newton-John, in the development and production of the Liv® Aid breast self-exam aid.

Scientists have identified some of the elusive downstream molecules that play a critical role in the development and progression of familial breast cancer. The research, published by Cell Press in the October 10th issue of the journal Molecular Cell, also identifies a compound found in grapes and red wine as an excellent candidate for treatment of some forms of breast cancer.

This year, an estimated 182,460 women will hear their doctors say, "You have breast cancer." More than 40,000 women will die from the disease.

The Wilmington News Journal on Tuesday examined efforts in Delaware that seek to raise breast cancer awareness among black and Hispanic women. While black and white women are diagnosed with breast cancer at similar rates, historically black women have had higher mortality rates from the disease, according to the state

deCODE genetics (Nasdaq:DCGN) has announced the launch of deCODE BreastCancer™, a new tool for assessing risk of the common forms of breast cancer. For the first time, a woman concerned about breast cancer can speak with her physician about a genetic test to better understand her lifetime risk of developing the common forms of the disease.

An Icelandic biotechnology company on Wednesday will begin offering a new genetic test to assess a woman's risk for the most common forms of breast cancer, reigniting concern about the proliferation of unregulated genetic tests, the Washington Post reports. FDA does not regulate screening tests when they are conducted by the labs that offer them.

A normal developmental protein that sometimes goes awry has been implicated in breast cancer. This discovery indicates the mechanism by which inappropriate expression of the Notch pathway may contribute to breast cancer. The breast cancer team at WEHI, led by Drs Jane Visvader and Geoff Lindeman from the Victorian Breast Cancer Research Consortium, have identified important roles for Notch genes in regulating breast development and function.

By 1st October 2008, the first day of breast cancer awareness month, 45,485 women had posted requests for support and advice on iVillage.co.uk's breast cancer board. Many of whom were worried and unsure about what lay ahead. Dismayed at the reported lack of information from GPs, community leaders at iVillage.co.uk, the UK 's leading women's website are today calling for greater support and information from the NHS about what lies beyond the lump.

Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists. The research study, led by UC's Nira Ben-Jonathan, PhD, says that BPA - a man-made chemical found in a number of plastic products, including drinking bottles and the lining of food cans - actually induces a group of proteins that protect cancer cells from the toxic effects of chemotherapy.

Reacting to a survey published in the British Journal of Cancer, which shows many older women are not aware that growing older can be a major risk factor for the disease, Kate Jopling, Head of Public Affairs for Help the Aged, says: "All too often older people get a rough deal from our healthcare services and these worrying findings show breast cancer services are no exception.